Related Experiment Videos
Cyclooxygenase 2: from inflammation to carcinogenesis
1Department of Pathology, Helsinki University Central Hospital, Molecular and Cancer Biology Research Program, Biomedicum Helsinki, University of Helsinki, Finland.
Novartis Foundation Symposium
|March 19, 2004
Summary
Cyclooxygenase-2 (COX-2) is an enzyme linked to inflammation and cancer. Inhibiting COX-2 shows promise in preventing and treating various cancers, making it a key target for chemoprevention strategies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cyclooxygenase (COX) enzymes catalyze the conversion of arachidonic acid to prostanoids.
- COX-1 is constitutively expressed and involved in physiological functions like stomach protection and platelet aggregation.
- COX-2 is an inducible enzyme implicated in inflammation, reproduction, and carcinogenesis.
Purpose of the Study:
- To investigate the role of COX-2 in various human malignancies.
- To evaluate the therapeutic potential of COX-2 inhibition in cancer chemoprevention.
Main Methods:
- Review of existing literature on COX-2 expression and function in cancer.
- Analysis of data from animal models of carcinogenesis.
- Examination of clinical data associating COX-2 expression with cancer prognosis and treatment outcomes.
Main Results:
- COX-2 expression is elevated in numerous human cancers and precursor lesions.
- Genetic deletion or pharmacological inhibition of COX-2 suppresses tumor growth in animal models.
- High COX-2 expression correlates with poor prognosis in digestive tract and breast adenocarcinomas.
- Selective COX-2 inhibitors reduced polyp burden in familial adenomatous polyposis patients.
Conclusions:
- COX-2 plays a significant role in cancer development and progression.
- Targeting COX-2 represents a promising strategy for cancer chemoprevention and treatment.
- Further research into selective COX-2 inhibitors is warranted for clinical application in oncology.